Format

Send to:

Choose Destination
See comment in PubMed Commons below
Neoplasia. 2012 Dec;14(12):1278-89.

Overcoming intratumor heterogeneity of polygenic cancer drug resistance with improved biomarker integration.

Author information

  • 1Department of Radiation Oncology, University of Michigan School of Medicine, Ann Arbor, MI 48109-2200, USA. alnawaz@umich.edu

Abstract

Improvements in technology and resources are helping to advance our understanding of cancer-initiating events as well as factors involved with tumor progression, adaptation, and evasion of therapy. Tumors are well known to contain diverse cell populations and intratumor heterogeneity affords neoplasms with a diverse set of biologic characteristics that can be used to evolve and adapt. Intratumor heterogeneity has emerged as a major hindrance to improving cancer patient care. Polygenic cancer drug resistance necessitates reconsidering drug designs to include polypharmacology in pursuit of novel combinatorial agents having multitarget activity to overcome the diverse and compensatory signaling pathways in which cancer cells use to survive and evade therapy. Advances will require integration of different biomarkers such as genomics and imaging to provide for more adequate elucidation of the spatially varying location, type, and extent of diverse intratumor signaling molecules to provide for a rationale-based personalized cancer medicine strategy.

PMID:
23308059
[PubMed - indexed for MEDLINE]
PMCID:
PMC3540957
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for PubMed Central
    Loading ...
    Write to the Help Desk